Reports Produced by Inpart 11 Dec 2024Antibody Therapy R&D trends and breakthrough innovations Check out a new report exploring R&D trends and breakthrough innovations leveraging antibodies to create potentially game-changing therapies, published by our parent company Inpart. December 11, 2024 Share WhatsApp Twitter Linkedin Email Produced by Inpart
Sponsored by Allucent 26 Nov 2024 Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of cancer treatment. November 26, 2024 - 8 minutesmins - By Will Chu Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Nov 2024 Six bispecific antibody companies you should know about Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients. November 19, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Nov 2024 What is Abcam’s founder, Jonathan Milner, up to? Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy. November 18, 2024 - 17 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Oct 2024 Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health. October 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Sep 2024 Two targets, one solution: The rise of bispecific antibodies Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like. September 18, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round. July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 16 Jul 2024 How a microbial expression update is driving biotech innovation Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides. July 16, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 26 Mar 2024 Large molecule manufacturing: addressing challenges with strategies for success Discover the landscape of large molecule manufacturing, exploring challenges, latest innovations, and winning strategies for success. March 26, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Mar 2024 6 biotech companies tackling antibiotic resistance Discover six antibiotic companies developing novel therapies in an attempt to overcome the global issue of antibiotic resistance. March 7, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […] June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email